Semaglutide is a synthetic long-acting glucagon-like peptide-1 (GLP-1) analogue and the most clinically characterised single-receptor GLP-1 agonist in published medical research. Engineered with a fatty acid side chain to enable albumin binding and minimise enzymatic degradation, it sustains receptor activation across approximately a week of subcutaneous exposure. Its published research base spans glycaemic control in type 2 diabetes (SUSTAIN), body-weight management (STEP), cardiovascular outcomes (SELECT), kidney disease (FLOW), and emerging research in addiction, Alzheimer's disease and inflammation — making it one of the most studied therapeutic peptides of the modern era.
Semaglutide is a 31-amino-acid peptide analogue of native GLP-1(7-37) with three structural modifications that distinguish it pharmacologically. An α-aminoisobutyric acid (Aib) substitution at position 8 confers DPP-4 resistance, blocking the rapid enzymatic degradation that limits native GLP-1 to a half-life of minutes. A C18 fatty diacid attached at lysine 26 via a γ-glutamic acid and two 8-amino-3,6-dioxaoctanoic acid (OEG) spacers enables strong, reversible binding to serum albumin — sustaining the molecule in circulation and supporting once-weekly subcutaneous dosing in published research protocols.
Semaglutide is a selective agonist at the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor expressed widely across pancreatic β-cells, gastric and intestinal smooth muscle, hypothalamic and brainstem satiety nuclei, the cardiovascular system, and several peripheral tissues. Activation drives glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, central appetite suppression, and a documented anti-inflammatory phenotype. Unlike Tirzepatide, Semaglutide has no significant GIP receptor activity — providing a clean pharmacological tool to study the pure GLP-1 mechanism.
Beyond its metabolic actions, Semaglutide's GLP-1R agonism is now studied for direct cardioprotective, renoprotective and neuroprotective effects that may operate independently of weight or glycaemic change. The breadth of published research outside the metabolic indication makes Semaglutide a uniquely well-characterised pharmacological probe of GLP-1 biology.
The STEP weight-management programme (STEP-1 through STEP-8+) studied Semaglutide 2.4 mg weekly in adults with obesity, consistently reporting mean weight reductions of approximately 14.9–17.4% over 68 weeks versus placebo. STEP-1 (NEJM, 2021) was the registration trial. SELECT (NEJM, 2023) extended the evidence base into cardiovascular outcomes, showing a 20% reduction in major adverse cardiovascular events in adults with established cardiovascular disease and overweight/obesity — the first clear demonstration of CV benefit from a weight-management indication.
The FLOW trial (NEJM, 2024) reported a 24% reduction in kidney disease progression in adults with T2D and chronic kidney disease, establishing a renal indication. Ongoing programmes are exploring Semaglutide in MASH, Alzheimer's disease (EVOKE), substance use disorder, and inflammatory disease. Semaglutide is approved as Ozempic (T2D, subcutaneous), Wegovy (obesity, subcutaneous), and Rybelsus (T2D, oral). The research-grade peptide supplied here is for in vitro laboratory work only.
STEP-1 (NEJM, 2021) randomised 1961 adults with obesity (no diabetes) to Semaglutide 2.4 mg weekly or placebo for 68 weeks. Mean weight reduction: 14.9% vs 2.4% with placebo. STEP-2 in T2D, STEP-3 with intensive lifestyle, STEP-4 (withdrawal extension), STEP-5 (2-year duration) and subsequent trials established consistency of effect across populations and durations.
STEP-5 (Nature Medicine, 2022) was particularly informative: 2-year follow-up showed weight loss was sustained at −15.2% vs −2.6% with placebo, with regain following discontinuation in the open-label extension data — a finding that has shaped the published understanding of GLP-1 pharmacology as a chronic-treatment paradigm.
SELECT (NEJM, Lincoff et al., 2023) — 17,604 adults with established CVD and overweight/obesity but without diabetes — reported a 20% reduction in MACE (CV death, MI, stroke) over a mean 39.8 months. This was the first weight-management compound to demonstrate CV outcome benefit in a primary trial, reshaping the field.
FLOW (NEJM, Perkovic et al., 2024) reported a 24% reduction in kidney-disease progression composite endpoint in adults with T2D + CKD. EVOKE (Alzheimer's disease) and emerging trials in MASH, OSA, and substance use disorder continue to read out. Preclinical research is also probing GLP-1R signalling in the central nervous system, joint inflammation, and tumour biology — Semaglutide is the most pharmacologically characterised GLP-1 tool compound available.